DK1558276T3 - Flavivirus-fusionsinhibitorer - Google Patents

Flavivirus-fusionsinhibitorer

Info

Publication number
DK1558276T3
DK1558276T3 DK03786613T DK03786613T DK1558276T3 DK 1558276 T3 DK1558276 T3 DK 1558276T3 DK 03786613 T DK03786613 T DK 03786613T DK 03786613 T DK03786613 T DK 03786613T DK 1558276 T3 DK1558276 T3 DK 1558276T3
Authority
DK
Denmark
Prior art keywords
fusion inhibitors
flavivirus fusion
flavivirus
inhibitors
fusion
Prior art date
Application number
DK03786613T
Other languages
Danish (da)
English (en)
Inventor
Robert F Garry
Srikanta Dash
David H Coy
Jane A Mckeating
Original Assignee
Univ Tulane
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Univ Rockefeller filed Critical Univ Tulane
Application granted granted Critical
Publication of DK1558276T3 publication Critical patent/DK1558276T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK03786613T 2002-11-08 2003-11-07 Flavivirus-fusionsinhibitorer DK1558276T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42474602P 2002-11-08 2002-11-08
PCT/US2003/035666 WO2004044220A2 (en) 2002-11-08 2003-11-07 Flaviviris fusion inhibitors

Publications (1)

Publication Number Publication Date
DK1558276T3 true DK1558276T3 (da) 2012-10-22

Family

ID=32312869

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03786613T DK1558276T3 (da) 2002-11-08 2003-11-07 Flavivirus-fusionsinhibitorer

Country Status (8)

Country Link
US (3) US7416733B2 (enExample)
EP (3) EP1558276B1 (enExample)
JP (2) JP5250179B2 (enExample)
AU (1) AU2003295427A1 (enExample)
CA (1) CA2503303A1 (enExample)
DK (1) DK1558276T3 (enExample)
ES (1) ES2390874T3 (enExample)
WO (1) WO2004044220A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
EP1797112B1 (en) 2004-09-29 2010-07-21 The Administrators of the Tulane Educational Fund Inhibitors of hepatitits c virus
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
AU2006311938A1 (en) * 2005-11-02 2007-05-18 Ambrx, Inc. Biosynthetic polypeptide fusion inhibitors
CA2643819C (en) * 2006-02-27 2018-11-27 Ilya Frolov Pseudoinfectious flavivirus and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
EP2202298A1 (en) * 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
US20130203655A1 (en) * 2010-02-12 2013-08-08 Margaret Kielian Methods for preventing or treating viral infection
WO2016037985A1 (en) * 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
KR101886286B1 (ko) * 2016-11-21 2018-08-10 주식회사 옵티팜 돼지파보바이러스 및 돼지열병바이러스에 대한 동시 항원성 복합 항원 단백질의 제조 방법
CN111454989B (zh) * 2020-04-04 2022-03-08 中国农业科学院兰州兽医研究所 一种嵌合型基因i型乙型脑炎病毒病毒样颗粒疫苗及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
DE4041304A1 (de) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw Von strukturproteinen des hepatitis c-virus abgeleitete polypeptide, testkits, die diese polypeptide enthalten und impfstoffe gegen infektionen von hepatitis c-viren
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
US6180109B1 (en) * 1994-06-17 2001-01-30 Instituut Voor Dierhouderij En Diergezondheid Nucleotide and polypeptide sequences of pestivirus strains
US6117640A (en) * 1995-05-02 2000-09-12 The United States Of America As Represented By The Secretary Of The Army Recombinant vaccine made in E. coli against dengue virus
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
EP1028972B1 (en) * 1997-11-06 2010-09-29 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
CA2330086A1 (en) * 1998-04-24 1999-11-04 Washington University Chimeras of hepatitis c virus and bovine viral diarrhea virus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
EP0982402A1 (en) * 1998-08-14 2000-03-01 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Pestivirus vaccination
AU5460900A (en) * 1999-06-04 2000-12-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious cdna clone of gb virus b and uses thereof
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU785216B2 (en) * 1999-09-17 2006-11-09 Keio University Humanin, a polypetide suppressing neuronal death
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector

Also Published As

Publication number Publication date
US7854937B2 (en) 2010-12-21
AU2003295427A8 (en) 2004-06-03
US7416733B2 (en) 2008-08-26
JP5250179B2 (ja) 2013-07-31
AU2003295427A1 (en) 2004-06-03
EP2360168A1 (en) 2011-08-24
EP1558276A2 (en) 2005-08-03
ES2390874T3 (es) 2012-11-19
CA2503303A1 (en) 2004-05-27
US8153360B2 (en) 2012-04-10
EP1558276A4 (en) 2006-09-13
US20110130328A1 (en) 2011-06-02
EP2338894A1 (en) 2011-06-29
WO2004044220A3 (en) 2005-05-06
JP2010280682A (ja) 2010-12-16
JP2006507328A (ja) 2006-03-02
EP1558276B1 (en) 2012-07-25
US20050271677A1 (en) 2005-12-08
WO2004044220A2 (en) 2004-05-27
US20090209464A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
AT5203U3 (de) Schweissaggregat
DK1505963T3 (da) Hepatitis C-inhibitorer
DE60234125D1 (de) E inhibitoren
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
EP1499336A4 (en) PROTEASE INHIBITORS
DE50311534D1 (de) Gewebeband-einrichtung
ATE427876T1 (de) Luftkissenboot
ATE318817T1 (de) Aza-arylpiperazine
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE349458T1 (de) Etonogestrelester
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
DK1558276T3 (da) Flavivirus-fusionsinhibitorer
ATA1572002A (de) Managementspleisskassette
ATA4142004A (de) Trägerverbau
DE60316425D1 (de) NF-kappaB-INHIBITOREN
ATE469773T1 (de) Zugöse
ATA19152002A (de) Hubkupplung
DE10360313A8 (de) Schweißvorrichtung
ATE396192T1 (de) N-sulfonylaminothiazole
DE10244834B8 (de) Suszeptometer
DE10241760B8 (de) Fackel
AT5889U3 (de) Brennholzspleisser
DE10211707A8 (de) Segmentstatormaschine
NO20043433L (no) Fremgangsmate